Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deferiprone - Apotex

Drug Profile

Deferiprone - Apotex

Alternative Names: CGP 37391; CMX 001 - CorMedix; CP 020; CP 20; CRMD-001; Ferriprox; Ferriprox Oral Solution; Kelfer; L1

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Royal Free and University College Medical School
  • Developer Apotex; Centre Hospitalier Univeristaire De Lille; CorMedix
  • Class Antianaemics; Antineoplastics; Antirheumatics; Pyridones; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase III Pantothenate kinase-associated neurodegeneration
  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease
  • Phase I/II Friedreich's ataxia
  • No development reported HIV infections
  • Discontinued Kidney disorders

Most Recent Events

  • 04 Sep 2019 ApoPharma completes a phase II trial in Parkinson's disease (Treatment-experienced, In adults, In the elderly) in Canada, France, Germany and United Kingdom (PO) (NCT02728843)
  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 06 Mar 2019 Phase-II clinical trials in Iron overload in Canada, USA (PO, Controlled release) (NCT03802916)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top